ADHD - Articles and news items

Amarantus forms Elto Pharma for CNS Disorders and MANF Therapeutics for Ophthalmology

Industry news / 18 April 2017 / Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus’ mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer’s Aggression and Parkinson’s disease Levodopa-induced Dyskinesia (PD-LID). Concurrently, Amarantus has formed the […]

ADHD market predicted to reach $13.9 billion by 2024

Industry news / 8 September 2016 / Niamh Louise Marriott, Digital Content Producer

The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%, according to research and consulting firm GlobalData…

Akili starts enrolment for trial of ADHD digital medicine treatment

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

Akili has started enrolment for its pivotal STARS-ADHD trial that will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO…

ADHD medication associated with decreased bone density in children

Industry news / 3 March 2016 / Victoria White

Results from a large study indicate that children on ADHD medication had lower bone mineral density in the femur, femoral neck and lumbar spine…

ADHD drug Adzenys addresses unmet need for patients, says GlobalData

Industry news / 12 February 2016 / Victoria White

The recent FDA approval of Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to GlobalData analyst…

2015 Excellence in ADHD Patient Group Awards: Patient advocacy at Shire

Blog / 20 October 2015 / Victoria White

In the run up to ADHD Awareness Week, European Pharmaceutical Review spoke with Tom Croce, Head of Global Patient Advocacy at Shire, to find out more about the awards and what makes Shire a ‘patient-centric’ company…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+